Alkermes Settles Teva LYBALVI Patent Suit; Generic Entry Delayed to November 2039
ALKS sits 77% above its 52-week low of $27.
Summary
Alkermes settled Teva's LYBALVI patent challenge, licensing Teva to launch a generic only from November 12, 2039 (May 12, 2040 with pediatric exclusivity). No cash or royalties change hands; the win is roughly 13 more years of exclusivity, pending FTC/DOJ review.
Key Events · Legal and Risk Events · ALKS
-
Teva LYBALVI Suit Settled
Alkermes subsidiaries signed a Confidential Settlement and License Agreement with Teva on November 6, 2026, resolving the New Jersey patent infringement suit over Teva's ANDA No. 220379 for all dosage strengths of LYBALVI.
-
Generic Entry Pushed to 2039
Teva gets a non-exclusive, royalty-free, non-transferable license to sell its ANDA products in the U.S. beginning November 12, 2039, or May 12, 2040 if Alkermes obtains pediatric exclusivity.
-
No Cash or Royalty Terms
Because the license is royalty-free, Alkermes receives no payment from Teva; the benefit is the deferred generic entry date rather than any proceeds.
-
Dismissal Filed, Agency Review Pending
The parties filed a joint Stipulation of Dismissal with Prejudice on November 9, 2026; the agreement remains subject to review by the U.S. Federal Trade Commission and the Department of Justice.
Analysis · ALKS · Life Sciences
Alkermes has ended its patent fight with Teva over LYBALVI, the schizophrenia/bipolar drug it acquired with Avadel, by granting Teva a royalty-free license that bars generic sales until November 12, 2039 (May 12, 2040 if pediatric exclusivity is granted). That preserves roughly 13 more years of exclusive LYBALVI sales, which matters because the Avadel deal already weighs on earnings — Q3 net income fell to $16.3M and the nine-month result was a $49.7M loss on Avadel-related interest, amortization and inventory step-up. The trade-off: no cash and no royalties flow from Teva; the value is purely the removal of litigation risk and the deferred entry date. FTC and DOJ review is still pending, so the terms are not yet final.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALKS was trading at $47.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $27.00 to $55.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.